Trials / Completed
CompletedNCT00833417
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients received vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismodegib, or withdrawal from the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vismodegib 150 mg | Vismodegib 150 mg was provided in hard gelatin capsules. |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2010-11-01
- Completion
- 2014-04-01
- First posted
- 2009-02-02
- Last updated
- 2015-05-20
- Results posted
- 2012-04-30
Locations
35 sites across 6 countries: United States, Australia, Belgium, France, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT00833417. Inclusion in this directory is not an endorsement.